NewcelX prices $1.55 million private placement at premium to market
NewcelX will sell shares and warrants at a 20% premium to its November 6, 2026 closing price, with proceeds aimed at advancing its type 1 diabetes cell therapy program.
SEC filing
2 stories
NewcelX will sell shares and warrants at a 20% premium to its November 6, 2026 closing price, with proceeds aimed at advancing its type 1 diabetes cell therapy program.
SEC filing
The deal gives NewcelX upfront cash and equity plus up to $55 million in milestones as it narrows focus to its cell-therapy pipeline for Type 1 diabetes.
SEC filing